The biotechnology industry has been hit hard by the current financial crisis and faces a future where efficiency and collaboration will be prerequisites for survival. During the last eight months, one study reported that "120 companies announced restructuring plans, including reprioritizing their programs and reduction of workforce. . ..[Of] the 120, 100 are small biotech companies and 20 are major pharma or biotech companies."
展开▼
